The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect fees for biosimilar biological products from October 2023 through September 2027. FDA dedicates these fees to expediting the review process for biosimilar biological products, facilitating the development of safe and effective biosimilar products for the American public.
FDA-TRACK: Biosimilar User Fee Act Procedural Notification Goals Summa
by Felicia Eddings, Pharm.D. | Sep 23, 2025 | News From Around The Web | 0 comments
Save More With Pill Pals®
Pill Pass® Drug List starts at only $6.99, and shipping is FREE. No Insurance Needed.
Learn More
Shop with Confidence at Pill Pals® - We're The EXPRESS Pharmacy
Secure checkout, SSL protection, and trusted shopping safeguards for Pill Pals® customers.



